Holders of Contingent Value Rights
General Information
UMB Bank, National Association (the “Trustee”) serves as the successor Trustee under the Contingent Value Rights Agreement, dated as of November 20, 2019 (the “CVR Agreement”), by and between Bristol-Myers Squibb Company (the “Company”) and Equiniti Trust Company (the “Original Trustee”) relating to the Company’s Contingent Value Rights (the “CVRs”).
On December 18, 2020, the Trustee delivered to the Company and the Original Trustee an Instrument of Removal, Appointment and Acceptance, dated as of December 9, 2020, pursuant to which (a) the Original Trustee was removed as Trustee under the CVR Agreement, (b) the Trustee was appointed as successor Trustee under the CVR Agreement, and (c) the Trustee accepted its appointment as Trustee under the CVR Agreement. By notice dated January 4, 2021, the Company notified Holders of the CVRs of the removal of the Original Trustee and the appointment of the Trustee as successor Trustee.
The Trustee has retained Katten Muchin Rosenman LLP to represent the Trustee in connection with its role as the Trustee and with respect to matters relating to the CVR Agreement. In addition, the Trustee has retained Dunn Isaacson Rhee LLP as lead trial counsel, Selendy Gay PLLC as litigation counsel and Cahill Gordon & Reindel LLP as special counsel.
Holders of CVRs (“CVR Holders”) with questions regarding the CVRs may review the information provided in this website.
CVR Holders may also contact the Trustee in writing as follows:
UMB Bank, National Association
120 South Sixth Street, Suite 1400
Minneapolis, MN 55402
Email: BristolMyersCVR@umb.com
Please note that the Trustee may conclude that a specific response to particular inquiries from individual CVR Holders is not consistent with equal and full dissemination of information to all CVR Holders. CVR Holders should not rely on the Trustee as their sole source of information concerning the CVRs. The Trustee makes no recommendations and gives no investment, financial, legal or other advice with respect to the matters herein or as to the CVRs generally.
Notices and Information for Holders of Contingent Value Rights
Notice to Holders re Denial of BMS Reconsideration Motion and Cross-Claim MTD - June 5, 2026
Notice to Holders re BMS Reconsideration Motion - January 16, 2026
Notice to Holders re Trustee Appeal and Second Amended Complaint - December 20, 2024
Notice to Holders re Rescheduled Hearing on Second BMS MTD - August 23, 2024
Notice to Holders re Updated Scheduling Order - July 31, 2024
Notice to Holders re Updated Scheduling Order and BMS MTD - February 26, 2024
Notice to Holders re Updated Scheduling Order and 10-19 Joint Status Letter - November 1, 2023
Notice to Holders re Updated Scheduling Order and 1-26 Joint Status Letter - February 15, 2023
Notice to Holders re Denial of BMS MTD - July 8, 2022
Notice to Holders re BMS MTD Complaint and Class Actions - May 19, 2022
Notice to Holders re Trustee Complaint and Prepaid Forward Agreement - June 9, 2021
Notice to Holders re Breach of CVR Agreement and Preservation Notice - March 9, 2021
Notice to Holders re Prepaid Forward Agreement - February 26, 2021
Notice to Holders re BMS Failure to Achieve CVR Milestones - February 25, 2021
Bristol Myers Supplemental Brief in Support of Motion to Dismiss - May 6, 2024
UMB Bank's Supplemental Opposition to Motion to Dismiss - April 29, 2024
Order Extending Scheduling Order - April 12, 2024
Bristol Myers Reply Memorandum ISO MTD - April_5, 2024
UMB OPPOSITION TO BMS MOTION TO DISMISS-March 15, 2024
2.2.24_BMY_Second_Motion_to_Dismiss
2.2.24_BMY_Memo_in_Support_of_Second_Motion_to_Dismiss
12.15.23_Order_Granting_Leave_to_File_Summary_Judgment_Motion
Joint Status Update dated 10.19.23
Updating Scheduling Order dated 8.3.23
Bristol Myers – Joint Status Letter – January 26-2023
Bristol_Myers-Civil_Case_Management_Plan_and_Scheduling_Order-2022-07-26
Bristol-Myers_-_Answer_July_8_2022
Bristol_Myers_-_Memorandum_Opinion_and_Order_-_June_24_2022
Bristol_Myers_Reply_Memorandum_in_Further_Support_of_Motion_to_Dismiss_the_Complaint_October_14-2021
Bristol_Myers-OPPOSITION_TO_DEFENDANTS_MOTION_TO_DISMISS_Sept_14-2021
Bristol_Myers_Exhibit_1_September_14-2021
Bristol_Myers_Exhibit_2_September_14-2021
Bristol_Myers_Exhibit_3_September_14-2021
Bristol_Myers_Exhibit_4_September_14-2021
Bristol_Myers_Exhibit_5_September_14-2021
Bristol_Myers_Exhibit_6_September_14-2021
Bristol_Myers_Exhibit_7_September_14-2021
Bristol Myers–Letter to The Depository Trust Company_6-21-2021
Bristol Myers–Letter to The Depository Trust Company_6-21-2021_Exhibit A
Bristol Myers-Complaint 6-3-2021
Bristol Myers-Complaint 6-3-2021-Exhibit A
Bristol Myers-Complaint 6-3-2021-Exhibit B
DE 122 Cross-Claim Stay Opinion 2026-05-21
DE 121 Joint Letter re Cross-Claims 2026-05-18
DE 120 Reconsideration Opinion 2026-05-07
DE 114 BMS Reply ISO MTD Cross-Claim
DE 113 EQ Opp. to BMS MTD Cross-Claim
DE 110 Reconsideration BMS Reply
DE 96 Opp to Motion for Reconsideration
DE 92 Answer to Amended Complaint
DE 91 Motion to Dismiss Equiniti Cross Claims
DE 88 Memorandum ISO Motion for Reconsideration
DE 85 - Opinion on 2024 MTD-December 1, 2025
DE 81 - EQ Cross Claim Complaint Only-November 14, 2025
2025.08.11 BMS Consolidation Objection
2025.08.11 UMB Consolidation Response
2025.05.27 Dkt 68_0 Main Document
UMB Memo of Law in Opposition to MTD
2025.03.06 Equiniti Answer to Amended Complaint
2025.03.06 BMS Memo of Law in Support of MTD